



## Overall **Programme Manager** for the PanACEA consortium

### **Description:**

The Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) is an EDCTP-funded consortium that aims to evaluate three different drugs (Moxifloxacin, Rifampicin and SQ109) in a drug development program. PanACEA will advance the development of therapeutics for shortening and simplifying TB treatment by (a) supporting regulatory-quality Phase IIa, IIb and Phase III clinical trials, and (b) developing enhanced clinical trial capacity in sub-Saharan Africa. By forming a network of six European research organizations, twelve sub-Saharan clinical trial sites, and three pharmaceutical companies, PanACEA will realize synergies across the proposed trials and develop processes, tools, and capacity for more efficient and effective future clinical trials for TB drug candidates currently in the development pipeline.

Each trial is managed independently but the chief investigators together form the governing body, the Chief Investigators group (CIG). They are advised by the PanACEA Programme Board that consists of all site principal investigators. The PanACEA Programme manager will manage the programme and function as the secretariat for the CIG and the Programme board.

His/her tasks include to

- Manage program wide activities which include capacity building, training, integrated monitoring and laboratory activities across the network and other joint task
- Coordinate the meetings and internal communication of the CIG and the three trials management groups.
- Coordinate the external communication of the CIG with the EDCTP and site investigators.
- Ensure the timely fulfillment of the overarching reporting requirements to EDCTP.
- Be a focal point and resource for overarching PanACEA inquiries from the sites.
- Organize PanACEA Program Board meetings and support the PanACEA chair in establishing an agenda and minutes

### **Your Qualification:**

- Minimum of B.Sc., M.Sc. or Diploma in Life Sciences, Ph.D. preferred
- Relevant experience in the conduct and management of ICH-GCP compliant, registration standard clinical trials possibly as Senior CRA or Clinical Study Manager
- Ability to work conceptually and have good management skills
- Excellent communication skills

We offer a competitive salary for this challenging position. The successful applicant will be located at one of our African Centres and will contribute to the selection of the appropriate location for the secretariat.

For further information, you can contact one of the Chief Investigators.

Please submit your electronic application to Georgette Plemper van Balen [G.PlempervanBalén@ulc.umcn.nl](mailto:G.PlempervanBalén@ulc.umcn.nl) by January 2010, at the latest.

PanACEA consists of:

**REMOX:** Rapid Evaluation of Moxifloxacin in Tuberculosis  
Chief Investigator: Stephen Gillespie,  
University College London, UK

[s.gillespie@medsch.ucl.ac.uk](mailto:s.gillespie@medsch.ucl.ac.uk)

++44 20 7794 0433

Alternate contact: Tim McHugh

University College London

[t.mchugh@medsch.ucl.ac.uk](mailto:t.mchugh@medsch.ucl.ac.uk)

++44 20 7472 6402

**SQ109:** Evaluation of a Novel TB Drug to Shorten and Simplify Tuberculosis Treatment

Chief Investigator: Michael Hoelscher,

Department of Infectious Diseases & Tropical Medicine,

University of Munich, Germany

[hoelscher@lrz.uni-muenchen.de](mailto:hoelscher@lrz.uni-muenchen.de)

++49 8921803830

**HIGHRIF:** Rapid Evaluation of High-Dose Rifampicin and other Rifamycins in Tuberculosis

Chief Investigator: Martin Boeree,

Radboud University Nijmegen Medical Centre, the Netherlands

[M.Boeree@ULC.umcn.nl](mailto:M.Boeree@ULC.umcn.nl)

++31 246859284